Vencedora do prêmio Nobel, classe de medicamentos baseados em RNAi está ao alcance dos brasileiros
A tecnologia da empresa Alnylam Pharmaceuticals, que explora o processo de RNA de interferência, é capaz de viabilizar o desenvolvimento de tratamentos que atuam na causa da doença. Referências: ¹ Simões MV et al. Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021....
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Huawei e Drauzio Varella ampliam parceria com foco em saúde preventiva
- Inteligência artificial das lava e seca LG personaliza o cuidado com as roupas
- LG inova com a LG xboom Stage 501: potência, design, tecnologia de ponta e bateria de 25 horas
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →